The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Sulacillin     (2R,5R,6S)-6-[[(2R)-2-amino- 2-phenyl...

Synonyms: LS-149730, AC1L3P1B, 94935-63-4, Ampicillin-sulbactam, Ampicillin-sulbactam mixt, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ampicillin-sulbactam


Psychiatry related information on Ampicillin-sulbactam

  • The ampicillin-sulbactam group had a significantly longer latency period (433 +/- 625 versus 143 +/- 165 hours, P = .03) and significantly fewer neonatal complications (five versus 20, P < .001) [6].

High impact information on Ampicillin-sulbactam


Chemical compound and disease context of Ampicillin-sulbactam


Biological context of Ampicillin-sulbactam

  • Human pharmacokinetics of ampicillin-sulbactam (1.5- and 3.0-g intravenous doses) were simulated in each model, and pharmacodynamic interactions were evaluated over one 6-h dosing interval [15].
  • The activities of ampicillin-sulbactam and amoxicillin-clavulanate were studied with 100 selected clinical Escherichia coli isolates with different beta-lactam susceptibility phenotypes by standard agar dilution and disk diffusion techniques and with a commercial microdilution system (PASCO) [16].
  • To examine the predictable effect of inoculum size on the kinetics of the antimicrobial action of ampicillin-sulbactam, five TEM-1 beta-lactamase-producing Escherichia coli strains were studied in an in vitro dynamic model at two different initial inocula (N0S) [17].
  • STUDY DESIGN: Before induction of labor, timed pregnant New Zealand White rabbits on day 29 of a 31-day gestation received no therapy or ampicillin-sulbactam 50 mg/kg intramuscularly as a single dose 2 to 8 hours before delivery [18].
  • This result should encourage a large multicenter trial to demonstrate whether ampicillin-sulbactam prophylaxis reduces patient mortality, and whether antibiotic resistance is increased in patients receiving prophylaxis [19].

Anatomical context of Ampicillin-sulbactam


Associations of Ampicillin-sulbactam with other chemical compounds


Gene context of Ampicillin-sulbactam


Analytical, diagnostic and therapeutic context of Ampicillin-sulbactam


  1. Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients. Kaye, K.S., Harris, A.D., Gold, H., Carmeli, Y. Antimicrob. Agents Chemother. (2000) [Pubmed]
  2. Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections. Gisby, J., Beale, A.S. Antimicrob. Agents Chemother. (1988) [Pubmed]
  3. Chemoprophylactic efficacy against experimental endocarditis caused by beta-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity. Bayer, A.S., Tu, J. Antimicrob. Agents Chemother. (1990) [Pubmed]
  4. Comparison of ampicillin-sulbactam regimens simulating 1.5- and 3.0-gram doses to humans in treatment of Escherichia coli bacteremia in mice. Lister, P.D., Sanders, C.C. Antimicrob. Agents Chemother. (1995) [Pubmed]
  5. Ampicillin-sulbactam is effective in prevention and therapy of experimental endocarditis caused by beta-lactamase-producing coagulase-negative staphylococci. Ramos, M.C., Ing, M., Kim, E., Witt, M.D., Bayer, A.S. Antimicrob. Agents Chemother. (1996) [Pubmed]
  6. Latency period after preterm premature rupture of membranes: a comparison of ampicillin with and without sulbactam. Lewis, D.F., Fontenot, M.T., Brooks, G.G., Wise, R., Perkins, M.B., Heymann, A.R. Obstetrics and gynecology. (1995) [Pubmed]
  7. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Grossman, R.F., Rotschafer, J.C., Tan, J.S. Am. J. Med. (2005) [Pubmed]
  8. Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam. Carmeli, Y., Castro, J., Eliopoulos, G.M., Samore, M.H. Antimicrob. Agents Chemother. (2001) [Pubmed]
  9. Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Aeschlimann, J.R., Hershberger, E., Rybak, M.J. Antimicrob. Agents Chemother. (2000) [Pubmed]
  10. Pharmacokinetics of ampicillin and sulbactam in pediatric patients. Nahata, M.C., Vashi, V.I., Swanson, R.N., Messig, M.A., Chung, M. Antimicrob. Agents Chemother. (1999) [Pubmed]
  11. Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis. Hoellman, D.B., Visalli, M.A., Jacobs, M.R., Appelbaum, P.C. Antimicrob. Agents Chemother. (1998) [Pubmed]
  12. Efficacy of ampicillin-sulbactam versus that of cefoxitin for treatment of Escherichia coli infections in a rat intra-abdominal abscess model. Rice, L.B., Carias, L.L., Shlaes, D.M. Antimicrob. Agents Chemother. (1993) [Pubmed]
  13. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection. Zinner, S.H., Gilbert, D., Dudley, M.N. Antimicrob. Agents Chemother. (1998) [Pubmed]
  14. Efficacy of oxacillin and ampicillin-sulbactam combination in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus. Thauvin-Eliopoulos, C., Rice, L.B., Eliopoulos, G.M., Moellering, R.C. Antimicrob. Agents Chemother. (1990) [Pubmed]
  15. Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions. Alexov, M., Lister, P.D., Sanders, C.C. Antimicrob. Agents Chemother. (1996) [Pubmed]
  16. Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes. Oliver, A., Pérez-Vázquez, M., Martínez-Ferrer, M., Baquero, F., De Rafael, L., Cantón, R. Antimicrob. Agents Chemother. (1999) [Pubmed]
  17. Net effect of inoculum size on antimicrobial action of ampicillin-sulbactam: studies using an in vitro dynamic model. Firsov, A.A., Ruble, M., Gilbert, D., Savarino, D., Manzano, B., Medeiros, A.A., Zinner, S.H. Antimicrob. Agents Chemother. (1997) [Pubmed]
  18. The effect of timing of single-dose transplacental ampicillin-sulbactam therapy for prevention of neonatal group B streptococcal colonization and bacteremia in a rabbit model. McDuffie, R.S., Blanton, S.J., Charland, S.L., Gibbs, R.S. Am. J. Obstet. Gynecol. (1996) [Pubmed]
  19. Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study. Acquarolo, A., Urli, T., Perone, G., Giannotti, C., Candiani, A., Latronico, N. Intensive care medicine. (2005) [Pubmed]
  20. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Blazquez, J., Baquero, M.R., Canton, R., Alos, I., Baquero, F. Antimicrob. Agents Chemother. (1993) [Pubmed]
  21. Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery. Martin, C., Cotin, A., Giraud, A., Beccani-Argème, M., Alliot, P., Mallet, M.N., Argème, M. Antimicrob. Agents Chemother. (1998) [Pubmed]
  22. A rabbit model for bacterially induced preterm pregnancy loss: intervention studies with ampicillin-sulbactam. McDuffie, R.S., Blanton, S.J., Shikes, R.H., Gibbs, R.S. Am. J. Obstet. Gynecol. (1991) [Pubmed]
  23. A prospective, double-blind, randomized, controlled clinical trial of ampicillin-sulbactam for preterm premature rupture of membranes in women receiving antenatal corticosteroid therapy. Lovett, S.M., Weiss, J.D., Diogo, M.J., Williams, P.T., Garite, T.J. Am. J. Obstet. Gynecol. (1997) [Pubmed]
  24. The value of chemoprophylaxis against Enterococcus species in elective cholecystectomy: a randomized study of cefuroxime vs ampicillin-sulbactam. Dervisoglou, A., Tsiodras, S., Kanellakopoulou, K., Pinis, S., Galanakis, N., Pierakakis, S., Giannakakis, P., Liveranou, S., Ntasiou, P., Karampali, E., Iordanou, C., Giamarellou, H. Archives of surgery (Chicago, Ill. : 1960) (2006) [Pubmed]
  25. Experimentally induced intrauterine infection causes fetal brain white matter lesions in rabbits. Yoon, B.H., Kim, C.J., Romero, R., Jun, J.K., Park, K.H., Choi, S.T., Chi, J.G. Am. J. Obstet. Gynecol. (1997) [Pubmed]
  26. Dissemination of IMP-1 metallo- beta -lactamase-producing Acinetobacter species in a Brazilian teaching hospital. Tognim, M.C., Gales, A.C., Penteado, A.P., Silbert, S., Sader, H.S. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America. (2006) [Pubmed]
  27. Pharmacokinetics of a combination preparation of ampicillin and sulbactam in turkeys. Fernández-Varón, E., Cárceles, C.M., Espuny, A., Marín, P., Escudero, E. Am. J. Vet. Res. (2004) [Pubmed]
  28. Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Firsov, A.A., Savarino, D., Ruble, M., Gilbert, D., Manzano, B., Medeiros, A.A., Zinner, S.H. Antimicrob. Agents Chemother. (1996) [Pubmed]
  29. Susceptibility and bactericidal activity studies of four beta-lactamase-producing enterococci. Patterson, J.E., Zervos, M.J. Antimicrob. Agents Chemother. (1989) [Pubmed]
  30. Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance. Lamp, K.C., Vickers, M.K. Antimicrob. Agents Chemother. (1998) [Pubmed]
  31. An evaluation of susceptibility testing methods for ampicillin-sulbactam using a panel of beta-lactamase-producing bacteria. Siu, L.K., Lo, J.Y., Cheng, W.L., Ho, P.L., Ng, W.S., Chau, P.Y. APMIS (1999) [Pubmed]
  32. Use of ampicillin-sulbactam for treatment of experimental meningitis caused by a beta-lactamase-producing strain of Escherichia coli K-1. Guerra-Romero, L., Kennedy, S.L., Fournier, M.A., Tureen, J.H., Täuber, M.G. Antimicrob. Agents Chemother. (1991) [Pubmed]
  33. Combination antibiotics and indomethacin in idiopathic preterm labor: a randomized double-blind clinical trial. Newton, E.R., Shields, L., Ridgway, L.E., Berkus, M.D., Elliott, B.D. Am. J. Obstet. Gynecol. (1991) [Pubmed]
WikiGenes - Universities